ReviewDrugs2011
Vaccination strategies in lymphomas and leukaemias: recent progress.
Review in Drugs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- HLA class I-specific nucleolin peptides induce therapeutic T cells in triple-negative breast cancer patients.International journal of biological sciences · 2026Article
- Recent Advancements in Nanomedicine for 'Cold' Tumor Immunotherapy.Nano-micro letters · 2021Review
- CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers.Frontiers in immunology · 2020Review
- Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy.Vaccines · 2018Review
- Article
- Review
- Article
- Differential ion mobility spectrometry coupled to tandem mass spectrometry enables targeted leukemia antigen detection.Journal of proteome research · 2014Article
- The determinants of tumour immunogenicity.Nature reviews. Cancer · 2012Review
- Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins.Frontiers in oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
The successful identification of a range of leukaemia-specific and lymphoma-specific antigens in recent years has stimulated efforts to develop therapeutic vaccination strategies. A number of clinical trials have established the safety and immunogenicity of vaccination against tumour antigens, although there are limited data on the clinical efficacy of this approach in haematological malignancies. After encouraging results of phase I/II trials using idiotype vaccines in lymphoma, the outcome of the three phase III trials has been somewhat disappointing. Several other promising strategies are currently being developed to improve these results, including optimization of antigen delivery. In myeloid leukaemias, clinical trials of vaccination with peptides derived from a number of leukaemia antigens, including WT1, PR1, RHAMM and BCR-ABL, have shown evidence of immunogenicity, but limited data are available on the clinical efficacy of this approach. In this review, we focus on the results of clinical trials of vaccination in leukaemia and lymphoma, and discuss potential strategies to enhance the efficacy of immunotherapy in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.